En route to BLA filing, Actinium details PhIII win for targeted radiotherapy in acute myeloid leukemia
Actinium Pharmaceuticals has spelled out the full Phase III data for its lead targeted radiotherapy — one that execs say presents a “practice expanding opportunity” in acute myeloid leukemia.
In the SIERRA trial, Actinium’s Iomab-B met the primary endpoint by helping 22% of patients achieve six-month durable complete remission following initial complete remission after a bone marrow transplant — compared to 0% of the control arm (p<0.0001).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.